Collegium Acquires AZSTARYS to Enhance ADHD Portfolio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy COLL?
Source: Newsfilter
- Strategic Acquisition: Collegium has acquired AZSTARYS for approximately $650 million, which is expected to significantly enhance its ADHD product portfolio and drive rapid growth through integration with its existing commercial infrastructure, thereby strengthening its competitive position in the market.
- Financial Guidance Upgrade: Collegium raised its 2026 product revenue guidance to a range of $865 million to $895 million, with adjusted EBITDA expectations also increased to $475 million to $500 million, reflecting the immediate financial benefits from the acquisition.
- Market Potential: AZSTARYS generated over 760,000 prescriptions in 2025 and is expected to contribute $60 million to $70 million in net revenue for the remainder of 2026, further solidifying Collegium's market position in ADHD treatment.
- Synergy Realization: The company anticipates achieving annual run rate synergies exceeding $50 million within twelve months post-acquisition, which will further enhance its financial position and support future cash flow generation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COLL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COLL
Wall Street analysts forecast COLL stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.830
Low
55.00
Averages
56.75
High
60.00
Current: 34.830
Low
55.00
Averages
56.75
High
60.00
About COLL
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Collegium Acquires AZSTARYS to Enhance ADHD Portfolio
- Strategic Acquisition: Collegium has acquired AZSTARYS for approximately $650 million, which is expected to significantly enhance its ADHD product portfolio and drive rapid growth through integration with its existing commercial infrastructure, thereby strengthening its competitive position in the market.
- Financial Guidance Upgrade: Collegium raised its 2026 product revenue guidance to a range of $865 million to $895 million, with adjusted EBITDA expectations also increased to $475 million to $500 million, reflecting the immediate financial benefits from the acquisition.
- Market Potential: AZSTARYS generated over 760,000 prescriptions in 2025 and is expected to contribute $60 million to $70 million in net revenue for the remainder of 2026, further solidifying Collegium's market position in ADHD treatment.
- Synergy Realization: The company anticipates achieving annual run rate synergies exceeding $50 million within twelve months post-acquisition, which will further enhance its financial position and support future cash flow generation.
See More
Collegium Pharmaceutical Q1 2026 Earnings Call Highlights
- Strategic Acquisition Progress: Collegium Pharmaceutical plans to acquire AZSTARYS for $650 million, which is expected to enhance its position in the ADHD market and extend revenue through patent protection until 2037, thereby accelerating the company's growth trajectory.
- Strong Financial Performance: In Q1, JORNAY prescriptions grew by 14% year-over-year, generating $38.9 million in net revenue, a 36% increase, while total product revenues reached $193.5 million, indicating stable performance in core products.
- Cash Flow and Liquidity: Collegium generated over $57.1 million in cash from operations in Q1, ending the quarter with over $421.8 million in cash, up $35 million from the end of 2025, enhancing the company's financial flexibility.
- Optimistic Market Outlook: Management reaffirmed its 2026 financial guidance, projecting total product revenues between $805 million and $825 million, with JORNAY revenue expected to be between $190 million and $200 million, reflecting confidence in future growth.
See More
Collegium Pharmaceutical Q1 Earnings Exceed Expectations
- Earnings Beat: Collegium Pharmaceutical reported Q1 2026 non-GAAP EPS of $1.76, surpassing expectations by $0.24, indicating strong profitability growth that boosts investor confidence.
- Revenue Growth: The company achieved total revenue of $193.5 million in Q1, an 8.8% year-over-year increase, exceeding market expectations by $9.04 million, reflecting sustained competitiveness in the market, particularly in pain management.
- Product Line Performance: The pain portfolio generated net revenues of $154.6 million, up 4% year-over-year, with Belbuca® and Xtampza®ER net revenues of $52.6 million and $50.8 million, respectively, growing 2% and 7%, demonstrating stable market demand and acceptance.
- Financial Guidance: Collegium projects 2026 product net revenues between $805 million and $825 million, with adjusted EBITDA expected to be between $455 million and $475 million, reflecting confidence in future growth, especially following the acquisition of Azstarys to expand its ADHD portfolio.
See More
Collegium Pharmaceutical Reports Strong Q1 Earnings Growth
- Significant Earnings Growth: Collegium Pharmaceutical reported a net income of $14.49 million for Q1, translating to $0.40 per share, a substantial increase from last year's $2.42 million and $0.07 per share, indicating a marked improvement in profitability.
- Strong Adjusted Earnings: Excluding special items, the company reported adjusted earnings of $69.21 million, or $1.76 per share, reflecting sustained growth and enhanced profitability in its core operations.
- Steady Revenue Increase: Q1 revenue rose by 8.9% to $193.52 million, up from $177.75 million last year, showcasing the company's success in meeting market demand and effective sales strategies.
- Optimistic Future Outlook: Collegium anticipates full-year revenue guidance of $805 million to $825 million for 2026, along with expected adjusted EBITDA of $455 million to $475 million, demonstrating confidence in future growth and strategic planning.
See More
Collegium Pharmaceutical to Announce Q1 Earnings on May 7
- Earnings Announcement: Collegium Pharmaceutical is set to release its Q1 2023 earnings on May 7 before market open, with consensus EPS estimates at $1.52, reflecting a 2.0% year-over-year increase, and revenue expectations at $184.46 million, up 3.7%, providing critical performance insights for investors.
- Performance Beat Record: Over the past two years, Collegium has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, indicating a strong track record of profitability and market performance, which may bolster investor confidence.
- Estimate Revision Trends: Despite no upward revisions in EPS estimates over the last three months, there have been four downward adjustments, and similarly, revenue estimates saw three downward revisions, reflecting a cautious market outlook on the company's future performance that investors should monitor closely.
- Acquisition Strategy: Collegium plans to acquire the ADHD medication Azstarys for up to $785 million, targeting a 31% revenue growth for Jornay by 2026, which not only expands its ADHD portfolio but also accelerates overall company growth, enhancing its competitive position in the market.
See More
Collegium Pharmaceutical Executive Sells Shares
- Insider Trading: David Dieter, Executive VP and General Counsel of Collegium Pharmaceutical, sold 6,224 shares on March 9, 2026, for $228,110, marking his first open-market transaction since joining the company.
- Stake Reduction: This sale reduced Dieter's direct holdings from 97,271 to 91,047 shares, impacting 6.4% of his equity stake, yet he retains approximately $3.39 million in shares, indicating ongoing confidence in the company.
- Planned Transaction: The sale was executed under a pre-scheduled 10b5-1 trading plan adopted on December 5, 2025, suggesting a cautious approach rather than a discretionary move, reflecting the executive's strategic market engagement.
- Business Transition: Collegium is undergoing a significant business transition with 2025 revenue of $631.7 million, a 6% increase, and projected 2026 revenue of $805-$825 million, highlighting growth potential in the ADHD treatment sector.
See More
Collegium Acquires AZSTARYS to Enhance ADHD Portfolio
- Strategic Acquisition: Collegium has acquired AZSTARYS for approximately $650 million, which is expected to significantly enhance its ADHD product portfolio and drive rapid growth through integration with its existing commercial infrastructure, thereby strengthening its competitive position in the market.
- Financial Guidance Upgrade: Collegium raised its 2026 product revenue guidance to a range of $865 million to $895 million, with adjusted EBITDA expectations also increased to $475 million to $500 million, reflecting the immediate financial benefits from the acquisition.
- Market Potential: AZSTARYS generated over 760,000 prescriptions in 2025 and is expected to contribute $60 million to $70 million in net revenue for the remainder of 2026, further solidifying Collegium's market position in ADHD treatment.
- Synergy Realization: The company anticipates achieving annual run rate synergies exceeding $50 million within twelve months post-acquisition, which will further enhance its financial position and support future cash flow generation.
See More
Collegium Pharmaceutical Q1 2026 Earnings Call Highlights
- Strategic Acquisition Progress: Collegium Pharmaceutical plans to acquire AZSTARYS for $650 million, which is expected to enhance its position in the ADHD market and extend revenue through patent protection until 2037, thereby accelerating the company's growth trajectory.
- Strong Financial Performance: In Q1, JORNAY prescriptions grew by 14% year-over-year, generating $38.9 million in net revenue, a 36% increase, while total product revenues reached $193.5 million, indicating stable performance in core products.
- Cash Flow and Liquidity: Collegium generated over $57.1 million in cash from operations in Q1, ending the quarter with over $421.8 million in cash, up $35 million from the end of 2025, enhancing the company's financial flexibility.
- Optimistic Market Outlook: Management reaffirmed its 2026 financial guidance, projecting total product revenues between $805 million and $825 million, with JORNAY revenue expected to be between $190 million and $200 million, reflecting confidence in future growth.
See More
Collegium Pharmaceutical Q1 Earnings Exceed Expectations
- Earnings Beat: Collegium Pharmaceutical reported Q1 2026 non-GAAP EPS of $1.76, surpassing expectations by $0.24, indicating strong profitability growth that boosts investor confidence.
- Revenue Growth: The company achieved total revenue of $193.5 million in Q1, an 8.8% year-over-year increase, exceeding market expectations by $9.04 million, reflecting sustained competitiveness in the market, particularly in pain management.
- Product Line Performance: The pain portfolio generated net revenues of $154.6 million, up 4% year-over-year, with Belbuca® and Xtampza®ER net revenues of $52.6 million and $50.8 million, respectively, growing 2% and 7%, demonstrating stable market demand and acceptance.
- Financial Guidance: Collegium projects 2026 product net revenues between $805 million and $825 million, with adjusted EBITDA expected to be between $455 million and $475 million, reflecting confidence in future growth, especially following the acquisition of Azstarys to expand its ADHD portfolio.
See More
Collegium Pharmaceutical Reports Strong Q1 Earnings Growth
- Significant Earnings Growth: Collegium Pharmaceutical reported a net income of $14.49 million for Q1, translating to $0.40 per share, a substantial increase from last year's $2.42 million and $0.07 per share, indicating a marked improvement in profitability.
- Strong Adjusted Earnings: Excluding special items, the company reported adjusted earnings of $69.21 million, or $1.76 per share, reflecting sustained growth and enhanced profitability in its core operations.
- Steady Revenue Increase: Q1 revenue rose by 8.9% to $193.52 million, up from $177.75 million last year, showcasing the company's success in meeting market demand and effective sales strategies.
- Optimistic Future Outlook: Collegium anticipates full-year revenue guidance of $805 million to $825 million for 2026, along with expected adjusted EBITDA of $455 million to $475 million, demonstrating confidence in future growth and strategic planning.
See More
Collegium Pharmaceutical to Announce Q1 Earnings on May 7
- Earnings Announcement: Collegium Pharmaceutical is set to release its Q1 2023 earnings on May 7 before market open, with consensus EPS estimates at $1.52, reflecting a 2.0% year-over-year increase, and revenue expectations at $184.46 million, up 3.7%, providing critical performance insights for investors.
- Performance Beat Record: Over the past two years, Collegium has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, indicating a strong track record of profitability and market performance, which may bolster investor confidence.
- Estimate Revision Trends: Despite no upward revisions in EPS estimates over the last three months, there have been four downward adjustments, and similarly, revenue estimates saw three downward revisions, reflecting a cautious market outlook on the company's future performance that investors should monitor closely.
- Acquisition Strategy: Collegium plans to acquire the ADHD medication Azstarys for up to $785 million, targeting a 31% revenue growth for Jornay by 2026, which not only expands its ADHD portfolio but also accelerates overall company growth, enhancing its competitive position in the market.
See More
Collegium Pharmaceutical Executive Sells Shares
- Insider Trading: David Dieter, Executive VP and General Counsel of Collegium Pharmaceutical, sold 6,224 shares on March 9, 2026, for $228,110, marking his first open-market transaction since joining the company.
- Stake Reduction: This sale reduced Dieter's direct holdings from 97,271 to 91,047 shares, impacting 6.4% of his equity stake, yet he retains approximately $3.39 million in shares, indicating ongoing confidence in the company.
- Planned Transaction: The sale was executed under a pre-scheduled 10b5-1 trading plan adopted on December 5, 2025, suggesting a cautious approach rather than a discretionary move, reflecting the executive's strategic market engagement.
- Business Transition: Collegium is undergoing a significant business transition with 2025 revenue of $631.7 million, a 6% increase, and projected 2026 revenue of $805-$825 million, highlighting growth potential in the ADHD treatment sector.
See More
